Very good news for the chemo subgroup. They had be
Post# of 72440
This is very good as it confirms B-OM is extremely effective in Chemotherapy patients. I look forward to seeing the results of the other subgroups. Maybe the weaker subgroups will benefit from a better formulation. Overall this makes me feel more confident in B-OM being the leader in at least part of the HNC market.